Facial redness in Japanese adolescents with atopic dermatitis treated with dupilumab: A case series
Journal of Allergy and Clinical Immunology: Global, 2023 This case series study is the first report of Japanese adolescents who experienced dupilumab facial redness after starting dupilumab treatment for refractory atopic dermatitis.
Shuhei Hara, MD +5 more
doaj +1 more source
Consensus on the Clinical Approach to Moderate-to-Severe Atopic Dermatitis in Spain: A Delphi Survey [PDF]
, 2020 Background. The purpose of this study was to gather information on the current assessment and management of patients with moderate-to-severe AD in routine daily practice. Methods.
Armario Hita, José Carlos +9 more
core +3 more sources
Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase
Scientific Reports, 2021 Dupilumab is a dual inhibitor of interleukin-4 and interleukin-13 and is mainly used to treat moderate-to-severe atopic dermatitis. Post-marketing safety data related to dupilumab have been accumulated, and it has been found that ocular surface diseases ...
Sunny Park +6 more
doaj +1 more source
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. [PDF]
, 2020 Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the ...
Ardeleanu, Marius +16 more
core +2 more sources
Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]
, 2020 Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C +3 more
core +1 more source
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults
Качественная клиническая практика, 2022 Target therapy of severe atopic dermatitidis (AD) is actual because AD has a high prevalence and social-economic burden. Target therapy consists of monoclonal antibodies (dupilumab) as well as janus kinase inhibitors (upadacitinib and baricitinib).
A. S. Kolbin +3 more
doaj +1 more source
Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]
, 2019 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus +3 more
core +1 more source
Journal of Cutaneous Immunology and Allergy, 2023 Objectives Alopecia areata (AA) often coexists with atopic dermatitis (AD). Recently, several reports suggested that dupilumab, an interleukin 4 receptor α‐antagonist, administration could be a promising medication not only for severe AD but also for AA ...
Masahiro Fukuyama +3 more
doaj +1 more source
International Journal of Women's Dermatology, 2019 Background: The mechanisms underlying eye-related complications with dupilumab are poorly understood. Objective: This study aimed to determine the incidence and characteristics of ocular complications with dupilumab and the prevalence of comorbid ...
Jodie Raffi, BA +4 more
doaj +1 more source
Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis
American Journal of Ophthalmology Case Reports, 2020 Purpose: To describe a case of corneal ulceration associated with dupilumab use for atopic dermatitis. Observations: A patient developed an inflammatory corneal ulcer 3 weeks after starting bi-weekly intravenous dupilumab therapy.
Gavin Li +2 more
doaj +1 more source